Stockreport

ResMed: Facing A Potentially Dream-Disrupting Dose - Strong Sell [Seeking Alpha]

ResMed Inc.  (RMD) 
Last resmed inc. earnings: 4/30 04:05 pm Check Earnings Report
PDF I rate RMD a strong sell due to the imminent threat from Apnimed's oral OSA drug AD109, which showed 47% efficacy in Phase 3 trials. AD109, if FDA-approved and adopte [Read more]